Pain Relief by Lubricating and Cushioning Knee joint

Anti-Inflammation
Bone Formation
Anti-Osteoclastogenesis
Cartilage Regeneration
 Prostrolane is designed for:
Pain Relief by Lubricating and Cushioning Knee joint
Anti-Inflammation
Bone Formation
Anti-Osteoclastogenesis
Cartilage Regeneration
[ Prostrolane is 5~6 injection regimen given at 4 weeks intervals that provides benefits up to 6 months. ]
Indication
- Intra-articular filler, Prostrolane is indicated for the treatment of pain in osteoarthritic joints and for the improvement of joint mobility through
the enhancement of synovial fluid viscoelasticity.
Composition
- Sodium Hyaluronate (1.5%) Phosphate Buffered Saline, Oligopeptide-92, Nonapeptide-25, Octapeptide-11, Heptapeptide-16, Decapeptide-23
Storage
- Store between 2℃ and 25℃, away from sunlight. Make sure there are no visible signs of damage to the packaging before use.
Package
- 1 x prefilled syringe, 2 x traceability labels
Precautions / Dosage and adverse events
- Refer to instruction for use.

Signaling pathway of PROSTROLANE intra articular filler

Rheumatoid Arthritis-Inducing signaling Target signaling for therapy

Prostrolane
complex
Prostrolane
e complex
lan
stro
RANKL
Proomplex LMWHA
c
a
TNF
ne RANK
ola TLR4 BMPR II
r o str plex TRAF6
P com MyD88 BMPRI
TNFR TRIF
TRADD ERK, JNK Smad 1/5/8 TAK1
TRAF2 IKKα Smad 4
IKKβ
RIP
IKK Y Smad 1/5/8 p38
AP-1
IkB Smad 4
Gene transcription
NKkB Osteocalcin
NFATc1 Osteopontin
Smad 1/5/8 ALP
Smad 4 Dlx5 Osteoprotegrin
NKkB RUNX2 Collagen type 2
SEB Integrin

Inflammatory cytokin CathepsinK

TRAP
TNF α , IL-1, IL-8,
Calcitonin Receptor
Osteoblast differentiation
MMP1
OSCAR NUCLEUS
RANKL

Inflammation Osteoclast differentiation BONE Formation

HA degradation (LMWHA)
Sustained Release & Peptide Technology
Prostrolane is 5~6 injection regimen given
[ Medical Device in formation of Filler ] at 4 weeks intervals that provides benefits up to 6 months.

Rheumatoid arthritis Healthy Knee joint

Octapeptide-11
Anti-Inflammation

Oligopeptide-92
Bone Formation
Anti-Osteoclastogenesis

Hyaluronic Acid Nonapeptide-25

Pain Relief Bone Formation
Anti-Osteoclastogenesis

Decapeptide-23
Anti-Inflammation
Heptapeptide-16
Anti-Inflammation
in-vitro study
A Pro-inflammatory Cytokine Gene Expression of Prostrolane complex B Inhibition of Pro-inflammatory Cytokines
Cell line: HaCaT keratinocyte cell line Method: ELISA test
Method: RT-PCR analysis Concentration: TNF-α 50ng/ml, Prostrolane complex 1ug/ml
Concentration: TNF-α 50ng/ml, Prostrolane complex 1ug/ml
IL-1β expression IL-8 expression
1 2 3
250 450
400
COX-2 COX-2 expression IL-1β expression 200

Relative rate (%)

Relative rate (%)

350
140 180 300
150
120 160 250
IL-1β 140 200
Relative rate (%)

Relative rate (%)

100 100
120 150
80 100
50 100
60 80
50
Actin 60
40 0 0
40
20 20 - + + - + +
TNF-α TNF-α
TNF-α - + + 0 0
1 2 3 1 2 3 Prostrolane
Prostrolane - - + - - + complex - - +
complex

When inflammation is stimulated by TNF-α and treated with Prostrolane complex, When inflammation is stimulated by TNF-α and treated with Prostrolane complex,
the expression of pro-inflammatory molecules, COX-2 and IL-1β, were decreased. the expression of pro-inflammatory cytokines, IL-1β and IL-8, was decreased.

C Inhibition of Osteoclast differentiation by Prostrolane complex D Osteoblast Differentiation analysis by Alkaline Phosphatase Staining
Osteoclastogenesis inhibition test Cell line: C2C12 osteoblast cell line
Cell line: RAW264.7 macrophage cell line Method: Alkaline phosphatase staining
Method: TRAP Staining kit Incubation: 4 days
Culture time: 5 days Concentration: BMP4 100ng/ml
Concentration: RANKL 10ng/ml Prostrolane complex Prostrolane complex Prostrolane complex
Control BMP4 1ug/ml 5ug/ml 10ug/ml
RANKL RANKL
+Prostrolane complex +Prostrolane complex
Control RANKL 1ug/ml 10ug/ml

TRAP assay was performed to evaluate the inhibition effect of Prostrolane complex
against RANKL-induced osteoclast differentiaton. Prostrolane complex protected Osteoblasts were treated with Prostrolane complex for 4 days and analyzed
osteoclast differentiation induced by RANKL using ALP staining method. Prostrolane complex increased alkaline phosphatase-
positive cells compared to control group in a dose-dependent manner.
TRAP: Osteoclast differentiaton marker protein

Clinical study
- Clinical study Walking Speed Before & After Prostrolane Injection

Subject 1 Pt: AD Subject 2 Pt: KK

0m 10m 0m 10m
Before 28s Before 30s
1st 1st
Injection After 14s
Injection After 11s

Before 22s Before 28s

2nd 2nd
Injection After 10s
Injection After 10s

Before 10s Before 22s

3rd 3rd
Injection After 8s
Injection After 10s

Subject 3 Pt: NM Subject 4 Pt: MK

0m 10m 0m 10m
Before 30s Before 26s
1st 1st
Injection After
Injection After
17s 11s

Before 28s Before 19s

2nd 2nd
Injection After 11s
Injection After 12s

Before 22s Before 16s

3rd 3rd
Injection After 8s
Injection After 11s
 CAREGEN CO., LTD.
Head Office : 46-38, LS-ro 91beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do 14119 South Korea
Tel. +82-31-420-9200 Fax. +82-31-452-3869 E-mail. sales@caregen.com
1st Manufacturing : 272 Gongdan-ro, Gunpo-si, Gyeonggi-do, South Korea
2nd Manufacturing : 270 Gongdan-ro, Gunpo-si, Gyeonggi-do, South Korea
Tel. +82-31-420-9364
Creative Village : 16-27, LS-ro 91beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, South Korea
CAREGEN UK LIMITED
Conveyit House, 28 Coity Road, Bridgend, CF31 1LR United Kingdom

www.caregen.com / www.renokin.com / www.dermaheal.co.kr / www.revofil.com / www.drcyj.com / www.drcyjhairfiller.com